Document text
Principal Investigator: James G. Kublin
Organization: FRED HUTCHINSON CANCER CENTER
Fiscal Year: 2024
Award: $74,999
Funding agency: NIH Office of the Director
PROJECT SUMMARY
ANNUAL TRANSLATIONAL HIV EARLY STAGE INVESTIGATOR (ESI) CONFERENCE
This R13 application requests continued NIH support for four annual conferences for Early Stage Investigators
(ESIs) conducting translational HIV vaccine, cure, immunology, and co-infection research with non-human
primates (NHPs). These meetings are organized contiguous with the NHP AIDS Symposium and gather ESIs
and mentors for scientific networking, career development, and training in translational science skills. In Year
1, the meeting will be held at the Tulane National Primate Center in New Orleans, LA in conjunction with the
NHP AIDS Symposium. The conferences are planned by a diverse advisory group of experts in the field
including scientists at all stages of their careers. K01 HIV/AIDS Scholars and mentors complete a needs
assessment to determine priority topics for the meeting. The advisory committee develops the meeting agenda
using the input from this needs assessment. Attendees at the ESI Conferences will participate in training and
skill-building activities on important translational scientific topics (e.g., cure, prevention, vaccine, and
therapeutic research; NHP models of TB and coinfections); mentoring opportunities with senior and peer
investigators (e.g., panel discussions on career development); skill building for research career development
training (e.g., ESI funding landscape, how to conduct research with HIV Vaccine Trials Network (HVTN),
manuscript writing); “Works in Progress” presentations; and organized networking opportunities with other ESIs
and senior investigators (e.g., receptions, speed dating, and small group discussions). The meeting has no
registration fee and travel scholarships will be awarded to talented ESIs, with priority for underrepresented
applicants, and K01 Scholars and mentors, thus providing opportunities for these groups to continue to interact
and support translational science. The inclusion of women, underrepresented minorities and individuals with
disabilities will be supported as speakers, attendees, and advisors, with a goal of creating a meeting
environment that is welcoming to diverse scientists. HVTN staff will organize the conference and will provide
further translational research opportunities by facilitating participation for 3 K01 Scholars at the annual HVTN
Full Group Meeting in Washington, DC. These conferences will fill a critical gap in scientific knowledge and
workforce development by ensuring that the next generation of diverse ESI are able to facilitate greater
translation of research between preclinical NHP studies and clinical trials. Building a workforce for the future
composed of scientists with strong translational skills is critical to ending the HIV epidemic and developing HIV
vaccines, therapeutics, and cure strategies.
Terms: <2019-nCoV vaccine><AIDS><AIDS Virus><AIDS/HIV><Acceleration><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Address><Advisory Committees><Award><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 vaccine><COVID-19 years><Cicatrix><Clinical><Clinical Treatment Moab><Clinical Trials><Collaborations><Communities><Development><Disabled Persons><Disabled Population><Education><Educational aspects><Engineering><Ensure><Environment><Epidemic><Evaluation><Event><Exposure to><Faculty><Fees><Funding><Future><Goals><Group Meetings><HIV><HIV Vaccine Trials Network><HIV vaccine><HIV/AIDS><HIV/AIDS Vaccines><HIV/Mtb><HIV/TB><HIV/mycobacterium tuberculosis><HIV/tuberculosis><HVTN><Handicapped><Hearing><Home><Human><Human Immunodeficiency Viruses><Immunology><Information Dissemination><Injectable><Intervention><Intervention Strategies><Investigators><Investments><Knowledge><LAV-HTLV-III><Laboratories><Learning><Lymphadenopathy-Associated Virus><M tuberculosis infection><M. tb infection><M. tuberculosis infection><M. tuberculosis/HIV><M.tb infection><M.tuberculosis infection><MTB infection><MTB vaccine><Manuscripts><Mediation><Mentors><Modeling><Modern Man><Monoclonal Antibodies><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><NIH><NIH RFA><National Institutes of Health><Needs Assessment><Negotiating><Negotiation><Peer Review><People with Disabilities><Persons><Persons with Disabilities><Phase><Position><Positioning Attribute><Prevention Research><Primates><Primates Mammals><Process><Reagent><Request for Applications><Research><Research Design><Research Personnel><Research Support><Researchers><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 vaccine><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><Scars><Scholarship><Science><Scientist><Secure><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Side><Speed><Study Type><TB infection><TB vaccine><Talents><Task Forces><Techniques><Therapeutic><Therapeutic Research><Time><Training><Translational Research><Translational Research Enterprise><Translational Science><Travel><Tuberculosis><Tuberculosis Vaccines><Underrepresented Ethnic Minority><Underrepresented Minority><United States National Institutes of Health><Vaccine Research><Vaccine for TB><Vaccine for Tuberculosis><Vaccines><Virus-HIV><Washington><Woman><Work><Workforce Development><Writing><advisory team><anti-TB vaccine><career><career development><co-infection><co-morbid><co-morbidity><coinfection><comorbidity><conference><convention><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccine><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><cost><data sharing><deploy vaccines><developmental><disabled individual><disabled people><disseminated TB><disseminated tuberculosis><dissemination of results><distribute vaccines><experience><homes><human immunodeficiency virus vaccine><individuals with disabilities><infection due to Mycobacterium tuberculosis><innovate><innovation><innovative><interest><interventional strategy><investigator training><mAbs><meeting><meetings><monoclonal Abs><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><new approaches><new vaccines><next generation><next generation vaccines><non-human primate><nonhuman primate><novel><novel approaches><novel strategies><novel strategy><novel vaccines><operation><operations><pandemic><pandemic disease><peer><pre-clinical><preclinical><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><skill acquisition><skill development><skills><study design><summit><symposia><symposium><timeline><translation research><translation research enterprise><translational investigation><translational investigator><translational research program><translational researcher><translational scientist><tuberculosis infection><tuberculous spondyloarthropathy><under-representation of minorities><under-represented minority><underrepresentation of minorities><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against M. tuberculosis><vaccine against Mtb><vaccine against Mycobacterium tuberculosis><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine against TB><vaccine against tuberculosis><vaccine candidates against SARS-CoV-2><vaccine candidates against tuberculosis><vaccine deployment><vaccine distribution><vaccine for novel coronavirus><vaccine platform><vaccine roll-out><vaccine rollout><vaccine study><vaccine trial><vaccine-related research><vaccines preventing COVID><vaccines to prevent COVID>